These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23050309)

  • 21. Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease.
    Boswood A; Smith S; Patteson M
    Vet Rec; 2011 Feb; 168(8):222. PubMed ID: 21493561
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema].
    Yamazaki Y; Matsumoto H; Takeda A; Takahashi T; Sasaki N; Takahashi M; Tsuji T; Fujikane T; Shimizu T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Aug; 35(8):847-53. PubMed ID: 9366158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.
    King JN; Hirakawa A; Sonobe J; Otaki H; Sakakibara N; Seewald W; Forster S
    J Vet Sci; 2018 Jan; 19(1):117-128. PubMed ID: 28693297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
    J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
    Wess G; Kresken JG; Wendt R; Gaugele J; Killich M; Keller L; Simak J; Holler P; Bauer A; Küchenhof H; Glaus T
    J Vet Intern Med; 2020 Nov; 34(6):2232-2241. PubMed ID: 32945575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Boswood A; Gordon SG; Häggström J; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
    J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.
    Kaplan JL; Visser LC; Gunther-Harrington CT; Ontiveros ES; Wittenburg LA; Palm CA; Stern JA
    J Vet Intern Med; 2022 Nov; 36(6):1892-1899. PubMed ID: 36098206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
    Smith PJ; French AT; Van Israël N; Smith SG; Swift ST; Lee AJ; Corcoran BM; Dukes-McEwan J
    J Small Anim Pract; 2005 Mar; 46(3):121-30. PubMed ID: 15789807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pimobendan and its use in treating canine congestive heart failure.
    Bowles D; Fry D
    Compend Contin Educ Vet; 2011 Nov; 33(11):E1. PubMed ID: 22101450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin transmembrane transporter is down-regulated in late-stage canine degenerative mitral valve disease.
    Scruggs SM; Disatian S; Orton EC
    J Vet Cardiol; 2010 Dec; 12(3):163-9. PubMed ID: 21036114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of pimobendan in the management of heart failure.
    Fuentes VL
    Vet Clin North Am Small Anim Pract; 2004 Sep; 34(5):1145-55. PubMed ID: 15325474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of pimobendan for mitral valve regurgitation in dogs.
    Kanno N; Kuse H; Kawasaki M; Hara A; Kano R; Sasaki Y
    J Vet Med Sci; 2007 Apr; 69(4):373-7. PubMed ID: 17485924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term Outcome of Irish Wolfhound Dogs with Preclinical Cardiomyopathy, Atrial Fibrillation, or Both Treated with Pimobendan, Benazepril Hydrochloride, or Methyldigoxin Monotherapy.
    Vollmar AC; Fox PR
    J Vet Intern Med; 2016; 30(2):553-9. PubMed ID: 26936799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study.
    Chetboul V; Lefebvre HP; Sampedrano CC; Gouni V; Saponaro V; Serres F; Concordet D; Nicolle AP; Pouchelon JL
    J Vet Intern Med; 2007; 21(4):742-53. PubMed ID: 17708394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of oral administration of pimobendan in cats with heart failure.
    Gordon SG; Saunders AB; Roland RM; Winter RL; Drourr L; Achen SE; Hariu CD; Fries RC; Boggess MM; Miller MW
    J Am Vet Med Assoc; 2012 Jul; 241(1):89-94. PubMed ID: 22720992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease".
    Corcoran B; Culshaw G; Dukes-McEwan J; French A; Smith S; Swift S
    J Vet Intern Med; 2008; 22(2):243; author reply 245. PubMed ID: 18371020
    [No Abstract]   [Full Text] [Related]  

  • 37. Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation.
    Disatian S; Ehrhart EJ; Zimmerman S; Orton EC
    J Heart Valve Dis; 2008 Jul; 17(4):402-11; discussion 412. PubMed ID: 18751470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study).
    Summerfield NJ; Boswood A; O'Grady MR; Gordon SG; Dukes-McEwan J; Oyama MA; Smith S; Patteson M; French AT; Culshaw GJ; Braz-Ruivo L; Estrada A; O'Sullivan ML; Loureiro J; Willis R; Watson P
    J Vet Intern Med; 2012; 26(6):1337-49. PubMed ID: 23078651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy.
    Borgarelli M; Haggstrom J
    Vet Clin North Am Small Anim Pract; 2010 Jul; 40(4):651-63. PubMed ID: 20610017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arteriosclerotic changes in the myocardium, lung, and kidney in dogs with chronic congestive heart failure and myxomatous mitral valve disease.
    Falk T; Jönsson L; Olsen LH; Pedersen HD
    Cardiovasc Pathol; 2006; 15(4):185-93. PubMed ID: 16844549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.